Add to ORKGCessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patient
Contains fulltext : 185786.pdf (publisher's version ) (Closed access)BACKGROUND: T...
Introduction. Post-transplant lymphoproliferative disorder (PTLD) is one of the most severe and ofte...
New classes of agents have sequentially increased the specificity of post-transplant immunosuppressi...
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders...
Background. The optimal reduction of immunosuppressive therapy (IST) in renal transplant patients wi...
Background: Post-transplant lymphoproliferative disorders (PTLD) are a complication of chronic immun...
International audiencePost-transplant lymphoproliferative disorder (PTLD) is an uncontrolled prolife...
Backround: Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a seriou...
Aim. The optimal management of IST in renal transplant patients with PTLD is uncertain. As chemother...
The article deals with medical and organizational issues of individually-adapted immunosuppressive t...
Background: One of the important causes of mortality and morbidity in kidney transplanted patients i...
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ tra...
The online version of this article, along with updated information and services, is located o
Background. A steroid-free immunosuppressive protocol may improve the general well-being of patients...
Item does not contain fulltextBACKGROUND: Because of the adverse events associated with the administ...
Contains fulltext : 185786.pdf (publisher's version ) (Closed access)BACKGROUND: T...
Introduction. Post-transplant lymphoproliferative disorder (PTLD) is one of the most severe and ofte...
New classes of agents have sequentially increased the specificity of post-transplant immunosuppressi...
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders...
Background. The optimal reduction of immunosuppressive therapy (IST) in renal transplant patients wi...
Background: Post-transplant lymphoproliferative disorders (PTLD) are a complication of chronic immun...
International audiencePost-transplant lymphoproliferative disorder (PTLD) is an uncontrolled prolife...
Backround: Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a seriou...
Aim. The optimal management of IST in renal transplant patients with PTLD is uncertain. As chemother...
The article deals with medical and organizational issues of individually-adapted immunosuppressive t...
Background: One of the important causes of mortality and morbidity in kidney transplanted patients i...
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ tra...
The online version of this article, along with updated information and services, is located o
Background. A steroid-free immunosuppressive protocol may improve the general well-being of patients...
Item does not contain fulltextBACKGROUND: Because of the adverse events associated with the administ...
Contains fulltext : 185786.pdf (publisher's version ) (Closed access)BACKGROUND: T...
Introduction. Post-transplant lymphoproliferative disorder (PTLD) is one of the most severe and ofte...
New classes of agents have sequentially increased the specificity of post-transplant immunosuppressi...